市場調查報告書
商品編碼
1549980
整形外科移植金黃色葡萄球菌感染診斷·治療的全球市場:診斷&治療區分·終端用戶·不同地區的預測 (~2032年)Global Staphylococcus Aureus Infection Diagnosis and Treatment for Orthopedic Implant Market Research Report Information by Diagnosis & Treatment, by End User, by Region Forecast till 2032 |
骨科植入物金黃色葡萄球菌感染診斷和治療的市場規模預計將從2022年的23.1億美元增長到2023年的24億美元,預測期內複合年增長率為4.89%,預計到2032年。預計會的。
使用植入物的骨科手術數量不斷增加,骨折發生率不斷增加,正在推動市場擴張。
由於骨科手術的增加,骨科植入物的金黃色葡萄球菌感染診斷和治療的需求不斷增加。例如,2023年7月,克里夫蘭診所(美國)宣布,美國每年進行約80萬例全膝關節置換術。此外,美國髖關節和膝關節外科醫生協會將假體關節感染 (PJI) 列為全髖關節置換術 (THA) 後的一個嚴重問題,特別是如果存在其他健康問題,預計會增加。金黃色葡萄球菌引起的感染比例從2008-2009年的26.3%上升到2020-2021年的40%。
區域見解
2022年,北美市場佔最大佔有率。這與北美骨科植入物中金黃色葡萄球菌感染的增加、良好的醫療基礎設施以及骨科手術數量的增加有關。
本報告提供全球整形外科移植金黃色葡萄球菌感染診斷·治療的市場調查,彙整市場定義和概要,市場成長的各種影響因素分析,市場規模的轉變·預測,各種區分·各地區的明細,競爭環境,主要企業簡介等資訊。
Global Staphylococcus Aureus Infection Diagnosis and Treatment for Orthopedic Implant Market Research Report Information by Diagnosis & Treatment {(Diagnosis [Microbiological Culture Test, Polymerase Chain Reaction, and Imaging Studies {Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and Ultrasonography}], Treatment(Antibiotics, Antimicrobial Therapy, and Surgery)}, by End User (Hospitals, Ambulatory Surgery Centers, and Others), by Region (North America, Europe, Asia-Pacific, and Rest of the World) Forecast till 2032
Staphylococcus aureus Infection Diagnosis and Treatment for Orthopedic Implants The market was valued at USD 2.31 billion in 2022. The staphylococcus aureus infection diagnostics and treatment for orthopedic implants market is expected to increase from USD 2.40 billion in 2023 to USD 3.87 billion by 2032, with a compound yearly growth rate (CAGR) of 4.89% over the forecast period. The increasing number of orthopedic procedures involving implants, as well as the increased incidence of fractures, are driving market expansion.
The growing number of orthopedic procedures is driving up the demand for staphylococcus aureus infection diagnosis and treatment for orthopedic implants. For example, in July 2023, Cleveland Clinic (US) announced that approximately 800,000 knee replacements are performed annually in the United States. Furthermore, the American Association of Hip and Knee Surgeons identifies prosthetic joint infection (PJI) as a serious concern following total hip arthroplasty (THA), particularly when other health issues are present, which increases the risk. The rate of infections caused by staphylococcus aureus increased from 26.3% in 2008-2009 to 40% between 2020 and 2021.
Market Segment insights
The Staphylococcus Aureus Infection Diagnosis and Treatment for Orthopedic Implant Market is classified by diagnosis and treatment, with diagnosis further subdivided into microbiological culture test, polymerase chain reaction, and imaging studies.
The Staphylococcus aureus Infection Diagnosis and Treatment for Orthopedic Implant Market is segmented by end user, which includes hospitals, ambulatory surgical centers, and others.
Regional insights
The report divides the market into five regions: the United States, Europe, China, the Middle East and North Africa, and the rest of the world. In 2022, the North American staphylococcus aureus infection diagnostic and treatment for orthopedic implants market held the greatest market share. This is related to the increased prevalence of staphylococcus aureus infection in orthopedic implants, excellent healthcare infrastructure, and an increase in the number of orthopedic procedures in North America.
The Europe staphylococcus aureus infection detection and treatment for orthopedic implants market has the second-largest market share due to an increasing elderly population and favorable reimbursement policies across the country. Furthermore, Germany has the largest market share for staphylococcus aureus infection diagnosis and treatment for orthopedic implants, while the UK is expected to be the fastest-growing market in the European region.
The Asia-Pacific staphylococcus aureus infection diagnostic and treatment market for orthopedic implants is predicted to develop significantly between 2023 and 2032. This is attributable to strong population increase, government initiatives and investments, and coordination among regional healthcare partners.
The rest of the world is divided into three regions: the Middle East, Africa, and Latin America. The staphylococcus aureus infection diagnosis and treatment for orthopedic implants market in the regions is expected to increase as a result of continuing research & development activities to create novel diagnostic technologies, medicines, and preventive methods.
Xellia Pharmaceuticals (Germany), Wellona Pharma (India), Schwitz Biotech (India), Merck KGaA (Germany), Thermo Fisher Scientific Inc (US), BioMerieux SA (France), Siemens Healthineers AG (Germany), Beckman Coulter Inc (US), Hoffmann-La Roche Ltd (Switzerland), and Pfizer Inc (US) are among the key companies in the Staphylococcus Aureus Infection Diagnosis and Treatment for Orthopedic Implant Market.